SCIENTIFIC PROGRAM   Registration Secretariat personnel will be present from 4:00 p.m. to 8:00 p.m. on Wednesday, October 3, 2007 on the 2nd floor promenade of the Hilton New York for registration and assistance to the participants. Scientific Session Schedule The scientific sessions will be scheduled as follows: Thursday, October 4, 2007 8:30 a.m. - 6:30 p.m. Friday, October 5, 2007 7:00 a.m. - 6:30 p.m. Saturday, October 6, 2007 8:30 a.m. - 6:30 p.m. Sunday, October 7, 2007 8:30 a.m. - 12:15 p.m.

A) PLENARY SESSIONS

THURSDAY, OCTOBER 4, 2007

WELCOME AND OPENING REMARKS - (8:30 - 8:45 a.m.)
R. Paoletti (Milan, Italy)
A.M. Gotto, Jr. (New York, NY, USA)

PLENARY SESSION 1 - (8:45 - 10:45 a.m.)
HDL

P. Barter (Sydney, Australia)
ANTIATHEROGENIC PROPERTIES OF HDL

J.-C. Fruchart (Lille, France)
HDL, REVERSE CHOLESTEROL TRANSPORT, AND NUCLEAR RECEPTORS

H.B. Brewer, Jr. (Washington, DC, USA)
UPDATE ON HDL METABOLISM AND POTENTIAL OF HDL AS A THERAPEUTIC AGENT IN THE TREATMENT OF CARDIOVASCULAR DISEASE

C. Sirtori (Milan, Italy)
DRUGS AFFECTING HDL

FRIDAY, OCTOBER 5, 2007

PLENARY SESSION 2 - (8:30 - 10:30 a.m.)
NUTRITION, DIABETES, AND CARDIOVASCULAR DISEASE

S.M. Grundy (Dallas, TX, USA)
METABOLIC SYNDROME: CLASSIFICATION, DIAGNOSIS, AND TREATMENT

A. Chait (Seattle, WA, USA)
OBESITY, INFLAMMATION, DIABETES, AND CARDIOVASCULAR DISEASE

Y. Matsuzawa (Osaka, Japan)
EMERGING THERAPEUTIC STRATEGY BASED ON ADIPOCENTRIC HYPOTHESIS

A.H. Lichtenstein (Boston, MA, USA)
DIET, DIETARY COMPONENTS, AND ATHEROSCLEROSIS

SATURDAY, OCTOBER 6, 2007

PLENARY SESSION 3 - (8:30 - 10:30 a.m.)
THE ATHEROSCLEROTIC PLAQUE: FROM BIOLOGY TO CLINIC

V. Fuster (New York, NY, USA)
EMERGING METHODS FOR ASSESSING THE ATHEROSCLEROTIC BURDEN / REGULATORY PERSPECTIVES ON NONINVASIVE METHODOLOGIES

F. Mach (Geneva, Switzerland)
INFLAMMATION AND IMMUNE SYSTEM IN ATHEROTHROMBOSIS 

C.M. Ballantyne (Houston, TX, USA)
CURRENT METHODOLOGIES FOR ASSESSING CARDIOVASCULAR RISK

A.M. Gotto, Jr. (New York, NY, USA)
TREATMENT OF CARDIOVASCULAR DISEASE: PRESENT AND FUTURE

SUNDAY, OCTOBER 7, 2007

PLENARY SESSION 4 - (8:30 - 10:30 a.m.)
HYPOLIPIDEMIC THERAPY AND ORGAN DISEASE: BEYOND THE HEART

J.P. Cooke (Stanford, CA, USA)
NEW INSIGHTS INTO PERIPHERAL ARTERIAL DISEASE AND ITS MANAGEMENT

P. Amarenco (Paris, France)
STROKE

H.N. Ginsberg (New York, NY, USA)
NONALCOHOLIC FATTY LIVER DISEASE: NEW INSIGHTS AND POTENTIAL NEW
TREATMENTS

M. Tonelli (Edmonton, AB, Canada)
DOES HYPOLIPEMIC THERAPY BENEFIT THE KIDNEY AS WELL AS THE HEART?

DEBATE - (11:00 - 12:00 p.m.)
PHARMACOLOGICAL THERAPY: INCREASING HDL vs DECREASING LDL

E.J. Schaefer (Boston, MA, USA)
HDL
vs
E. Stein (Cincinnati, OH, USA)
LDL

The Scientific Program will also include:

B) SUPPORTED SYMPOSIA

• ATHEROSCLEROSIS, LDL-C, hs-CRP, AND HDL-C: MULTIPLE EFFECTS OF INTENSIVE STATIN THERAPY
  S.M. Grundy (Dallas, TX, USA) - S.E. Nissen (Cleveland, OH, USA) - P.M. Ridker (Boston, MA, USA)
  
  
• BENEFITS OF STATIN THERAPY IN PATIENTS: NEW DIRECTIONS IN THETREATMENT OF ATHEROSCLEROSIS
  P. Deedwania (San Francisco, CA, USA) - J.C. LaRosa (Brooklyn, NY, USA) - J. Shepherd (Glasgow, UK) - D. Waters (San Francisco, CA, USA)
  
  
• BEYOND STATIN MONOTHERAPY: RAISING HDL-C, LOWERING CVD RISK
  P.J. Barter (Sidney, AUSTRALIA) - H.B. Brewer, Jr. (Whashington, DC, USA) - K.E. Watson (Los Angeles, CA, USA)
  
  
• CHOLESTEROL BALANCE, LIPOPROTEIN METABOLISM, AND CARDIOVASCULAR RISK
  D.E. Cohen (Boston, MA, USA) - E.A. Fisher (New York, NY, USA) - J.J.P. Kastelein (Amsterdam, The Netherlands)
  
  
• THE ENDOCANNABINOID SYSTEM AS A NEW APPROACH TO REDUCING RISK FOR CARDIOVASCULAR DISEASE
  L.J. Aronne (New York, NY, USA) - D. Cota (Cincinnati, OH, USA) - V. Di Marzo (Naples, Italy) - S. Klein (St. Louis, MO, USA)
  
  
• MANAGEMENT OF MIXED HYPERLIPIDEMIA: BEYOND LDL CHOLESTEROL
  C.M. Ballantyne (Houston, TX, USA) - M. Davidson (Chicago, IL, USA) H.N. Ginsberg (New York, NY, USA) - W.S. Harris (Sioux Falls, SD, USA)
  
  
• NOVEL APPROACHES TO REDUCING LDL OR ATHEROGENIC LIPOPROTEINS: BEYOND STATINS? 
  R. Laaksonen (Tampere, Finland) - M. Shiomi (Kobe, Japan) - E. Stein (Cincinnati, OH, USA) - A.S. Wierzbicki (London, UK)
  
  
• TARGETING HDL IN THE MANAGEMENT OF MIXED DYSLIPIDEMIA: THE NEXT FRONTIER IN CV RISK REDUCTION
  B.G. Brown (Seattle, WA, USA) - L. Ose (Oslo, Norway) - D.J. Rader (Philadelphia, PA, USA)
  
  
• TREATING RESIDUAL RISK: REDUCING TRIGLYCERIDES
  W.V. Brown (Atlanta, GA, USA) - J.-C. Fruchart (Lille, France) - A.M. Gotto, Jr. (New York, NY, USA)
  
  
• WHERE DOES INSULIN RESISTANCE START? A DEBATE
  Jointly organized by the Metabolic Syndrome Institute
  G. Boden (Philadelphia, PA, USA) - S. Del Prato (Pisa, Italy) - J.-C. Fruchart (Lille, France) - E. Horton (Boston, MA, USA)- F. Sacks (Boston, MA, USA)

C) WORKSHOPS (The Workshops will include Invited Lectures and Selected Oral Communications)

• ALIGNING PHARMACEUTICAL INNOVATION WITH MEDICAL NEED: THE POTENTIAL IMPACT ON THE DEVELOPING WORLD
  S.P. Kishore (New York, NY, USA)
  
  
• ANTIOXIDANTS
  I. Jialal (Davis, CA, USA)
  DIETARY FACTORS THAT MODULATE INFLAMMATION
  
  L. Bowman (Oxford, UK) SHORT- AND LONG-TERM EFFECTS OF ANTIOXIDANT VITAMIN SUPPLEMENTATION ON CARDIOVASCULAR EVENTS: A LARGE RANDOMIZED CONTROLLED TRIAL
  
  
• ATHEROSCLEROTIC PLAQUE
  A. Newby (Leeds, UK)
  LIPIDS, EXTRACELLULAR PROTEASES, AND PLAQUE INSTABILITY
  
  G. Steiner (Toronto, ON, Canada)
  DIABETES AND CORONARY RISK
  
  
• HDL
  G. Franceschini (Milan, Italy)
  LIPOPROTEIN ACCEPTOR FUNCTION IN CELL CHOLESTEROL EFFLUX: INSIGHTS FROM GENETIC HDL DISORDERS
  
  A. Tall (New York, NY, USA)
  ABC TRANSPORTERS, CHOLESTEROL EFFLUX, AND CETP INHIBITION
  
  C. Ehnholm (Helsinki, Finland)
  THE ROLE OF PLTP IN REVERSE CHOLESTEROL TRANSPORT
  
  
• LIPID LOWERING THERAPY
  E. Leitersdorf (Jerusalem, Israel)
  TREATMENT TO TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA: IS IT A "MET NEED"?
  
  A. Corsini (Milan, Italy)
  PHARMACOKINETIC CONSIDERATIONS IN COMBINED LIPID LOWERING THERAPY
  
  
• DIABETES AND CVD
  M.-R. Taskinen (Helsinki, Finland)
  WHY IS DIABETES AND ATHEROSCLEROSIS A FATAL COMBINATION?
  
  I. Tabas (New York, NY, USA)
  THE IMPACT OF OBESITY AND DIABETES ON MACROPHAGE APOPTOSIS IN ADVANCED ATHEROSCLEROSIS
  
  
• DOES CARDIOMETABOLIC RISK INTEGRATE METABOLIC SYNDROME? - Jointly organized with International Chair on Cardiometabolic Risk
  S.M. Grundy (Dallas, TX, USA)
  METABOLIC SYNDROME: AN UPDATE ON THE CURRENT DEBATE
  
  M. Stern (San Antonio, TX, USA)
  METABOLIC SYNDROME: QUESTIONING THE CONCEPT
  
  H.B. Brewer, Jr. (Washington, DC, USA)
  THE GLOBAL CARDIOMETABOLIC RISK INTEGRATES METABOLIC SYNDROME
  
  
• FATTY ACIDS, OMEGA-3, AND CVD
  W.S. Harris (Sioux Falls, SD, USA)
  THE OMEGA-3 INDEX: A NEW RISK FACTOR FOR SUDDEN CARDIAC DEATH?
  
  F. Sacks (Boston, MA, USA)
  HOW MUCH AND WHAT TYPE OF FAT IS OPTIMAL TO PREVENT CORONARY
  HEART DISEASE AND DIABETES
  
  
• GENETICS AND CVD
  J. Ordovas (Boston, MA, USA)
  NUTRITION AND GENETICS: PARTNERS IN CARDIOVASCULAR HEALTH AND DISEASE
  
  A.J. Lusis (Los Angeles, CA, USA)
  INTEGRATIVE GENETIC APPROACH TO UNDERSTANDING COMPLEX GENETIC AND ENVIRONMENTAL INTERACTIONS IN ATHEROSCLEROSIS
  
  
• HDL AND REVERSE CHOLESTEROL TRANSPORT
  D. Rader (Philadelphia, PA, USA)
  UPDATE ON MOLECULAR REGULATION OF REVERSE CHOLESTEROL TRANSPORT
  
  F. Bernini (Parma, Italy)
  REVERSE CHOLESTEROL TRANSPORT AS A PHARMACOLOGICAL TARGET
  
  
• IMAGING
  J.-C. Tardif (Montreal, QC, Canada)
  CORONARY IMAGING FOR THE ASSESSMENT OF NOVEL ANTI-ATHEROSCLEROTIC AGENTS
  
  Z.A. Fayad (New York, NY, USA)
  MULTIMODALITY (PET/CT, MR, AND CT) IMAGING OF THE ATHEROSCLEROTIC PLAQUE: IMPLICATIONS FOR NEW REGRESSION CLINICAL TRIALS
  
  E. Tremoli (Milan, Italy)
  RESULTS OF THE IMPROVE STUDY
  
  
• INFLAMMATION AND CVD
  F. Crea (Rome, Italy)
  INFLAMMATION AND ACUTE VASCULAR EVENTS
  
  R. Tracy (Burlington, VT, USA)
  INFLAMMATION AND THE CHRONIC DISEASES OF OLDER AGE
  
  
• LIPID METABOLISM
  I. Goldberg (New York, NY, USA)
  FATTY TISSUES: GETTING IT IN AND STORING IT UP
  
  R. Zechner (Graz, Austria)
  LIPOLYSIS: EFFECTS ON LIPID- AND ENERGY-HOMEOSTASIS
  
  
• METABOLIC SYNDROME
  R. Carmena (Valencia, Spain)
  MANAGEMENT OF DYSLIPIDEMIA IN THE METABOLIC SYNDROME
  
  R.H. Eckel (Denver, CO, USA)
  CUTTING THROUGH THE CONTROVERSIES OF THE METABOLIC SYNDROME
  
  
• NEW HYPOLIPIDEMIC DRUGS (1^st part)
  J.J.P. Kastelein (Amsterdam, The Netherlands)
  ANTISENSE APOB mRNA INHIBITION: FROM PROMISE TO PRACTICE
  
  
• NEW HYPOLIPIDEMIC DRUGS (2^nd part)
  A. Remaley (Bethesda, MD, USA)
  A BI-HELICAL APOA-I MIMETIC PEPTIDE: EFFECT ON CHOLESTEROL EFFLUX AND ON ATHEROSCLEROSIS IN MICE
  
  
• NUCLEAR RECEPTOR AND LIPID METABOLISM
  M. Crestani (Milan, Italy)
  NUCLEAR RECEPTORS AND COREGULATORS IN THE CONTROL OF CELLULAR METABOLISM
  
  B. Staels (Lille, France)
  THE NUCLEAR RECEPTOR FXR: A DRUG TARGET FOR THE METABOLIC SYNDROME?
  
  
• NUTRITION AND CVD
  R.M. Krauss (Oakland, CA, USA)
  DIETARY EFFECTS ON ATHEROGENIC DYSLIPIDEMIA OF METABOLIC SYNDROME
  
  D.J.A. Jenkins (Toronto, ON, Canada)
  A DIETARY PORTFOLIO TO REDUCE BOTH LIPID AND OTHER RISK FACTORS FOR CHD
  
  C. Galli (Milan, Italy)
  MACRO AND MICRO LIPID NUTRIENTS AND CARDIOVASCULAR DISEASES
  
  
• SPECIAL POPULATIONS
  J.M. Foody (New Haven, CT, USA)
  MANAGEMENT OF DYSLIPIDEMIA IN WOMEN
  
  J. Shepherd (Glasgow, UK)
  MANAGING VASCULAR RISK IN THE ELDERLY
  
  K. Watson (Los Angeles, CA, USA)
  LIPIDS, ETHNICITY, AND RISK:  HOW LIPID LEVELS MEAN DIFFERENT THINGS IN DIFFERENT RACES
  
  
• STEM CELLS IN CVD
  Q. Xu (London, UK)
  VASCULAR REPAIR BY STEM CELLS
  
  S. Rafii (New York, NY, USA)
  CONTRIBUTION OF PRO-ANGIOGENIC HEMATOPOIETIC CELLS TO REVASCULARIZATION OF ISCHEMIC TISSUES

D) SELECTED ORAL COMMUNICATIONS
The Scientific Program Committee will choose the best submitted abstracts to be included as Oral Communications in the Workshops.

E) POSTERS

• POSTER DISCUSSIONS Thursday, October 4, through Saturday, October 6, 2007, 10:30 a.m. - 4:30 p.m. daily.
  
  
• RECEPTION Saturday, October 6, 2007, 6:30 p.m. - 8:00 p.m.
  All registered participants are invited to attend the Young Investigator Poster Awards presentation and reception.